PCN22 The Effect of Groundbreaking Medical Therapy on the Incidence of Disease: A Case Study of Rituximab and Non-Hodgkin’s Lymphoma  by Rotella, P. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A71
ing docetaxel, an H3 and a BTA. Docetaxel-treated patients are younger than those 
receiving an H3.
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Objectives: Treatment for metastatic melanoma (mM) has evolved rapidly with 
the recent approval and reimbursement of new therapies. At the end of 2013, four 
new therapies, vemurafenib, ipilimumab, drabrafenib and trametinib were avail-
able for treatment of specific groups of patients with metastatic melanoma. Our 
objective is to compare the drug treatment sequences at centers in Canada during 
the time periods prior to and after availability of the new therapies. MethOds: The 
study used ONCO-CAPPS, a proprietary database of patient chart abstractions col-
lected through regular survey of physician panels. The data includes demographic 
details as well as disease markers, and a summary of the patients’ cancer treat-
ments from the time of diagnosis. Data from the time periods 2007 and 2013 were 
used to identify patients with metastatic melanoma and document their sequence 
of treatments. Conventional treatments include the older therapies: dacarbazine 
(DTIC), carboplatin-paclitaxel, lomustine, interferon and interleukin-2. Results: 
In 2007, 53 patients with mM were treated in first-line (1st) line and the major-
ity received a conventional therapy. Twenty-one of these patients progressed and 
received second-line (2nd) line therapy; 62% of them received a conventional therapy 
while 38% received an investigational agent. In 2013, 157 patients with mM were 
treated in 1stline; 47%, 10% and 43% of these received a conventional therapy, an 
investigational agent and a new therapy, respectively. Of those who progressed, 
18%, 11% and 71% received a conventional therapy, an investigational agent and a 
new therapy, respectively. cOnclusiOns: With the availability of newer options, a 
greater proportion of patients are being treated with these agents. The proportion 
of patients being treated with an investigational agent in 2nd line has decreased. 
Older agents continue to be used and the use of the newer therapies is dependent 
on patient characteristics and reimbursement guidelines.
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Objectives: The development of new medical therapies can have a profound effect 
on the epidemiology of a disease, especially when that development represents the 
first efficacious treatment. Rituximab was the first monoclonal antibody therapy 
for cancer, gaining FDA approval in 1997 in the United States (US) to treat non-
Hodgkin’s lymphoma (NHL). Rituximab’s positive impact on mortality has been 
well-documented. The potential effect of rituximab on the incidence of NHL is 
necessary to understand the full epidemiological impact of the drug. This study 
aimed to investigate that effect. MethOds: Age-adjusted incidence rates of NHL 
were modeled over time using Poisson regression, allowing a different slope for 
change in yearly rate before and after 1997. This allows assessment of whether 
the incidence rate was accelerating, decelerating, or did not change after 1997. To 
determine the optimal change-point for incidence of NHL, the model was repeated 
for each year within the study period and Akaike information criteria (AIC) were 
compared. The year with the lowest AIC was considered the optimal change-point. 
This analysis utilized the Surveillance, Epidemiology, and End Results (SEER) 9 inci-
dence data, which covers the time period 1973 -2010 (accessed using SEER*Stat 
software, version 8.1.2). Results: From 1973 -2010, there were 239,118 total cases 
of NHL documented in SEER. The model estimated an increase in incidence of 1.9% 
per year prior to 1997, compared to an estimated increase of only 0.5% per year 
from 1997 -2010. Comparison of AIC’s identified 1990 as the optimal change-point 
(annual incidence increase pre-1990: 2.4%; post-1990: 0.8%). cOnclusiOns: The 
incidence of NHL in the US has been increasing fairly steadily since 1973, though it 
has been increasing more slowly in recent years, and nearly stabilized after 1997. 
In fact, this deceleration appears to have started around 1990, prior to the approval 
and availability of rituximab.
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Objectives: Pancreatic cancer is the 4thleading cause of adult cancer mortality 
in the United States with a 5-year survival rate of approximately 6%. ACE inhibi-
tors and ARBs have been shown to inhibit tumor angiogenesis in pancreatic cells 
in both in-vitro and murine model studies. Previous research studies exploring a 
relationship between these agents and patients with pancreatic cancer used several 
different methods leading to unclear results. We conducted a large population-based 
study to examine overall survival differences in patients with pancreatic cancer 
taking ACE inhibitors or ARBs. MethOds: We used the Italian Emilia-Romagna 
Region (RER) health care database to conduct a retrospective cohort study following 
approximately 4 million adults (≥ 18) from 2003 to 2011. The RER database captures 
fully-linkable demographic, hospital discharge, outpatient pharmacy, and proce-
dure codes for all residents of the region. Patients were classified by resection and 
metastases based on surgical procedures and secondary malignancies. We used a 
Cox-proportional hazard model for each time-dependent medication exposure to 
minimize potential immortal-time-bias. Results: We identified a total of 8,281 
patients diagnosed with pancreatic cancer from 2003 to 2011 in the RER. After 
adjusting for covariates, the Cox-proportional hazards model using time-dependent 
exposure suggested that, among pancreatic cancer patients, those exposed to ACE 
Objectives: To characterize safety and efficacy outcomes of albumin-bound pacli-
taxel (nab-paclitaxel) in MBC in the United States since its approval in 2005 using 
health insurance claims data. MethOds: A retrospective claims analysis was con-
ducted using the Optum Research Database (United Health affiliate). The analysis 
included females aged ≥ 18 years diagnosed with MBC (≥ 2 claims of BC diagnosis 
separated by ≥ 30 days and ≥ 2 claims of metastatic spread) prior to nab-paclitaxel 
initiation who had complete medical coverage and pharmacy benefits, ≥ 6 months 
of continuous enrollment in a US health insurance plan from January 2005 through 
September 2012, no other primary malignancy, and no prior nab-paclitaxel therapy. 
Data were supplemented by Social Security Death Index sources. Cohorts were 
determined by line of therapy, nab-paclitaxel regimen, and schedule. Descriptive 
statistics were used to characterize outcomes. Endpoints included time to treat-
ment discontinuation (TTD), overall survival (OS), and safety. Results: Among 
664 eligible patients, most were between 40-69 years of age (88%) and had received 
nab-paclitaxel as ≥ second-line therapy (74%), monotherapy (61%), and weekly (71%). 
Bevacizumab (22%) and HER2-targeted therapies (9%) were used as combination 
partners. Median TTD and OS were 6.1 and 17.4 months, respectively. By line of 
therapy (first, second, and ≥ third), TTD was 7.1, 6.6, and 5.3 months and OS was 
22.7, 17.4, and 15.1 months. Median OS was similar when nab-paclitaxel was used 
in combination or as monotherapy (18.7 and 16.8 months) and weekly or every 3 
weeks (18.6 and 17.4 months). No new safety signals were observed. cOnclusiOns: 
Outcomes in this real-world patient population were consistent with clinical trial 
data, affirming the effectiveness and manageable safety profile of nab-paclitaxel in 
patients with MBC. This analysis will also help evaluate the benefit of nab-paclitaxel 
in patients aged ≥ 70 years.
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Objectives: Estimate the incremental cost-effectiveness ratio (ICER) of D+T versus 
vemurafenib and dacarbazine for BRAFV600 mutation-positive MM from the UK NHS 
perspective. MethOds: A partitioned-survival model with 3 states (progression-
free survival [PFS], post-progression survival, and death) and a lifetime horizon 
was developed. Treatment benefits were measured as gains in quality-adjusted 
life-years (QALYs). PFS and overall survival (OS) were derived from indirect treatment 
comparisons (ITCs) of D+T (from the Phase II BRF113220 study) versus vemurafenib 
(BRIM-3) and dacarbazine (BREAK-3). Latest OS data were adjusted for confounding 
effects of treatment switching, permitted upon progression in all studies. Safety 
data were from aforementioned trials. Costs were from the literature, a physician 
survey, and assumptions. Costs of medications to the NHS (incorporating avail-
able patient-access schemes), post-study anticancer therapy, routine and adverse 
event (AE) management, treatment initiation, and death were included. Utility data 
for D+T were derived from BREAK-3, with adjustment for differences in response 
and incidence of AEs. Deterministic and probabilistic sensitivity analyses were 
performed. Results: ITCs showed D+T significantly improved PFS versus vemu-
rafenib (hazard ratio [HR] 0.38; 95% CI, 0.19–0.74) and dacarbazine (0.14; 0.08–0.28) 
and suggested improved OS, although not statistically significant (0.42; 0.09–1.97 
versus vemurafenib and 0.26; 0.05–1.27 versus dacarbazine). Treatment with D+T 
was associated with a gain in QALYs versus vemurafenib and dacarbazine. The 
ICER for D+T was £50,603/QALY versus vemurafenib and £49,804/QALY versus dac-
arbazine. cOnclusiOns: Based on results of a Phase II trial and an ITC, D+T offers 
improved PFS and OS versus vemurafenib and dacarbazine. Further, considering 
NICE’s criteria for life-extending, end-of-life treatments, D+T may be cost-effective 
compared with vemurafenib, the NHS’s current standard of care for patients with 
BRAFV600 mutation-positive MM, although conclusions must await ongoing model-
ling on the basis of the Phase III, COMBI-D trial.
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Objectives: Treatment for metastatic castrate-resistant prostate cancer (mCRPC) 
has evolved rapidly with the introductions of abiraterone, denosumab and cabazi-
taxel in 2011 and enzalutamide in 2013 and the subsequent funding of these 
new agents. Our objective is to describe the treatments used after a diagnosis of 
mCRPC in Canada. MethOds: The study used ONCO-CAPPS, a proprietary database 
of patient chart abstractions collected through regular survey of physician panels. 
The data includes the stage of the disease along with a summary of treatment 
from diagnosis. Data from 2011 and 2013 were used to identify patients with 
mCRPC and to describe the treatments used. Hormone therapies are grouped as fol-
lows: H1 is Luteinizing-Hormone-Releasing Hormone analogs, H2 is anti-androgens 
while H3 is ketoconazole, prednisone, abiraterone or enzalutamide. Chemotherapy 
includes docetaxel and cabazitaxel. Pamidronate, zoledronic acid or denosumab are 
bone-targeted agents (BTA). Results: All patients with mCRPC are treated with 
a combination of hormones, with or without docetaxel and/or a BTA. In 2011, the 
proportions of mCRPC patients who were treated with regimens containing H1, H2 
and H3 were 93%, 43% and 12% respectively. In 2013, the proportions of mCRPC 
patients who were treated with regimens containing H1, H2 and H3 were 86%, 37% 
and 35% respectively. Between 2011 and 2013, the proportions of patients treated with 
a regimen containing docetaxel increased from 14% to 22% and the proportions of 
patients receiving an injectable BTA increased from 42% to 66%. In this period, the 
average age of patients treated with docetaxel was 69 years while that of patients 
treated with an H3 was 73 years. cOnclusiOns: With the introduction of the new 
agents, a greater proportion of mCRPC patients are treated with a regimen contain-
